Techniques and Outcomes of Salvage Robot-Assisted Radical Prostatectomy (sRARP).


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
12 2020
Historique:
received: 01 03 2020
accepted: 03 05 2020
pubmed: 29 5 2020
medline: 23 7 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

Salvage Robot-Assisted Radical Prostatectomy (sRARP) has been described as feasible treatment for the management of localised prostate cancer (PCa) recurrence after primary treatment. However, no large reports have published cancer and quality outcomes. To report perioperative, functional and oncologic outcomes of sRARP in patients with localised PCa recurrence. We retrospectively evaluated 106 patients with local recurrence eligible for sRARP. Surgery was performed using the DaVinci Si system similar to the standard approach but with adaptation to the primary treatment. Peri-operative outcomes included 90-day complication rate. Functional outcomes included rates of incontinence and erectile dysfunction. Oncological outcomes included tumour staging, margin rate and recurrence. Primary treatment was High Intensity Focused Ultrasound (HIFU) in 59 (56%) patients, 27 (25%) radiotherapy, 10 (9%) seed brachytherapy, 8 (8%) solitary androgen deprivation therapy (ADT), one (1%) cryotherapy and one (1%) electroporation / Nanoknife. Median follow-up was 2.1 years. 90-day complication rate was 8%. At two years or more, 50% were fully continent and 33% were socially continent. Continence rates tended to be better after focal compared to whole-gland treatments. Erectile dysfunction was present in 95%. Positive surgical margin rate was 39%. Biochemical recurrence occurred in 13% and local or metastatic recurrence in 11%. sRARP is technically more challenging but is a feasible option in high-volume centres for treatment of recurrent PCa. Patients should be counselled that functional outcomes are inferior to primary RARP. Adjustment of surgical technique according to the primary treatment is key for good surgical outcomes. We report our experience with sRARP for the management of localised PCa recurrence after primary treatment. This represents a feasible approach with acceptable peri-operative complications and cancer outcomes. Functional outcomes are inferior to RARP in the primary setting.

Sections du résumé

BACKGROUND
Salvage Robot-Assisted Radical Prostatectomy (sRARP) has been described as feasible treatment for the management of localised prostate cancer (PCa) recurrence after primary treatment. However, no large reports have published cancer and quality outcomes.
OBJECTIVE
To report perioperative, functional and oncologic outcomes of sRARP in patients with localised PCa recurrence.
DESIGN, SETTING, AND PARTICIPANTS
We retrospectively evaluated 106 patients with local recurrence eligible for sRARP.
SURGICAL PROCEDURE
Surgery was performed using the DaVinci Si system similar to the standard approach but with adaptation to the primary treatment.
MEASUREMENTS
Peri-operative outcomes included 90-day complication rate. Functional outcomes included rates of incontinence and erectile dysfunction. Oncological outcomes included tumour staging, margin rate and recurrence.
RESULTS AND LIMITATIONS
Primary treatment was High Intensity Focused Ultrasound (HIFU) in 59 (56%) patients, 27 (25%) radiotherapy, 10 (9%) seed brachytherapy, 8 (8%) solitary androgen deprivation therapy (ADT), one (1%) cryotherapy and one (1%) electroporation / Nanoknife. Median follow-up was 2.1 years. 90-day complication rate was 8%. At two years or more, 50% were fully continent and 33% were socially continent. Continence rates tended to be better after focal compared to whole-gland treatments. Erectile dysfunction was present in 95%. Positive surgical margin rate was 39%. Biochemical recurrence occurred in 13% and local or metastatic recurrence in 11%.
CONCLUSIONS
sRARP is technically more challenging but is a feasible option in high-volume centres for treatment of recurrent PCa. Patients should be counselled that functional outcomes are inferior to primary RARP. Adjustment of surgical technique according to the primary treatment is key for good surgical outcomes.
PATIENT SUMMARY
We report our experience with sRARP for the management of localised PCa recurrence after primary treatment. This represents a feasible approach with acceptable peri-operative complications and cancer outcomes. Functional outcomes are inferior to RARP in the primary setting.

Identifiants

pubmed: 32461073
pii: S0302-2838(20)30343-2
doi: 10.1016/j.eururo.2020.05.003
pii:
doi:

Types de publication

Journal Article Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

885-892

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

R De Groote (R)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK; Department of Urology, Onze Lieve Vrouw Hospital Aalst, Aalst, Belgium. Electronic address: degroote.ruben@gmail.com.

A Nathan (A)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

E De Bleser (E)

Department of Urology, Ghent University Hospital, Ghent, Belgium.

N Pavan (N)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK; Department of Medicine, Surgery and Health Sciences, Urological Clinic, University of Trieste, Trieste, Italy.

A Sridhar (A)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

J Kelly (J)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

P Sooriakumaran (P)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

T Briggs (T)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

S Nathan (S)

Department of Urology, University College London Hospital. NHS Foundation Trust. London. UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH